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Antioxidants and antioxidant treatment in diseaseAntioxidants react with and detoxify reactive free radicals. In mam-
mals, antioxidants consist of smallmolecules and redoxenzymes that pre-
vent or modulate free radical damage. Molecules such as vitamin E,
vitamin C, and glutathione are examples of the former, while superoxide
dismutase, catalase, and glutathione peroxidase are examples of the latter.
Free radicals are produced naturally in organelles such as the mito-
chondria, and Mn-superoxide dismutase is resident in mitochondria
to modulate superoxide radical levels in this organelle. Tissue resident,
as well as dietary/supplementary sources of antioxidants hold some
promise for treatment of disease, and some of these approaches to the
treatment and/or prevention/modulation of disease are discussed in
this Special Issue.
When the rate of production of free radicals eclipses the rate of
their being scavenged by antioxidants, oxidative or nitrosative stress
(depending on the radical type) is said to exist. Oxidative/nitrosative
stress can damage essential and/or large numbers of cells in various
organs, potentially leading to diminution of tissue function and pro-
motion of pathogenesis. Examples of such oxidative stress-related
diseases/disorders include neurodegenerative disorders (such as Alz-
heimer disease, Huntington disease, Down syndrome), neurotrauma,
kidney disease, cystic ﬁbrosis, various types of cancer, chronic ob-
structive pulmonary disease, pain, and aging. Each of these conditions
is discussed in this Special Issue in the context of oxidative stress and
antioxidants as potential therapies for these diseases/disorders.
This special issue of BBA—Molecular Basis of Disease on Antioxi-
dants and Antioxidant Treatment of Disease is the culmination of
months of work by the various authors for which we are very grateful.
However, we would be remiss not to mention the extraordinary effort
of the BBA/Elsevier staff who have been so helpful in bringing this spe-
cial issue to fruition, particularly Ms. Melissa Murray in San Diego and
Ms. Andy Deelen in Amsterdam, to whom we say thank you.
To the reader: It is our belief that this Special Issue provides both
basic and applied understanding of antioxidants and their use in a
wide variety of diseases. Certain principles arise from these excellent
papers, amongwhich is the recognition that the effective use of antiox-
idants in patients with different diseases requires knowledge of: (a)
how the antioxidants react to neutralize free radicals (direct or indirect
action); (b) cellular location of the antioxidants (cytosol, membrane bi-
layer, organelle) relative to the foci of themajor sources of free radicals;
and (c) the inherent antioxidant status of the subjects being treated
with antioxidants. This Special Issue addresses each of these issues
and provides examples of diseases/disorders in which antioxidant ther-
apy may be an effective strategy. In so doing we also touch in multiple
ways on the contradictions and controversies that currently exist in
the ﬁeld of antioxidant therapeutics, whereby previous studies that0925-4439/$ – see front matter © 2012 Published by Elsevier B.V.
doi:10.1016/j.bbadis.2012.02.020employed antioxidant therapy have failed, and other studies are pre-
sented whereby antioxidant therapies were observed to be efﬁcacious.
Such studies highlight that there is a role for antioxidant based thera-
peutics, but that it is clearly not a one size ﬁts all proposition. Much
more investigation is warranted as the new generation of antioxidant
therapies are being designed and implemented, with treatment begin-
ning in earlier stages of disease onset, and outcomes linked to docu-
mented suppression of oxidative stress. We hope and trust that you
will enjoy this Special Issue of BBA—Molecular Basis of Disease on Anti-
oxidants and Antioxidant Therapy in Disease.
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